采用不同技术进行根治性放疗的早期声门型喉癌患者的治疗结果

Outcome of Early-Stage Glottic Laryngeal Carcinoma Patients Treated with Radical Radiotherapy Using Different Techniques.

作者信息

Cetinayak Oguz, Dogan Ersoy, Kuru Ahmet, Akturk Nesrin, Aydin Barbaros, Umay Cenk, Er Ilhami, Akman Fadime

机构信息

Department of Radiation Oncology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.

Dokuz Eylul University Faculty of Medicine, Department of Otorhinolaryngology Head and Neck Surgery, Izmir, Turkey.

出版信息

J Oncol. 2019 Nov 6;2019:8640549. doi: 10.1155/2019/8640549. eCollection 2019.

DOI:10.1155/2019/8640549

PMID:31781218

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6874992/

Abstract

PURPOSE

The aim was to evaluate the treatment outcomes and prognostic characteristics of patients with early-stage glottic laryngeal carcinoma who underwent radical radiotherapy (RT) with different techniques.

PATIENTS AND METHODS

Radiotherapy was applied using the 2D conventional technique between 1991 and 2004 (130 patients), 3DCRT until 2014 (125 patients), and by VMAT until January 2017 (44 patients). Clinical T stages were 38 (12.7%) for Tis, 209 (69.9%) for T1, and 52 (17.4%) for T2. Radiotherapy technique and energy, anterior commissure involvement, and stage were analyzed as prognostic factors.

RESULTS

The median total dose was 66 (50-70) Gy, and median follow-up time was 72 (3-288) months; 5-year disease-specific survival (DSS) rates were 95.8%, 95.5%, and 88.6%, respectively, in Tis, T1, and T2 stages. In multivariate analyses, anterior commissure involvement was found significant for all survival and local control rates. The patients treated with VMAT technique had better local control and DSS rates. However, these results were not statistically significant.

CONCLUSION

In early-stage laryngeal carcinomas, radical RT is a function sparing and effective treatment modality, regardless of treatment techniques.

摘要

目的

旨在评估采用不同技术进行根治性放疗（RT）的早期声门型喉癌患者的治疗效果和预后特征。

患者与方法

1991年至2004年期间采用二维传统技术进行放疗（130例患者），2014年前采用三维适形放疗（3DCRT，125例患者），截至2017年1月采用容积调强弧形放疗（VMAT，44例患者）。临床T分期为Tis期38例（12.7%）、T1期209例（69.9%）、T2期52例（17.4%）。将放疗技术与能量、前联合受累情况及分期作为预后因素进行分析。

结果

总剂量中位数为66（50 - 70）Gy，中位随访时间为72（3 - 288）个月；Tis期、T1期和T2期的5年疾病特异性生存率（DSS）分别为95.8%、95.5%和88.6%。多因素分析显示，前联合受累对所有生存率和局部控制率均有显著影响。采用VMAT技术治疗的患者局部控制率和DSS率更高。然而，这些结果无统计学意义。